Vitrafy Secures IMV Deal and Accelerates U.S. Launch as Cash Position Supports Commercial Push

Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has shared an announcement.

Vitrafy Life Sciences reported a strong second quarter of FY2026, highlighted by an exclusive 12‑month strategic commercial agreement with global animal-assisted reproduction leader IMV Technologies to co-develop a market-ready cryopreservation solution for farm animals and aquaculture, expected to deliver recurring service and milestone revenues and potentially lead to a long-term deal. The company advanced its human health strategy with continued U.S. Military phase II testing for blood platelet cryopreservation, the arrival of its first Guardion device in California and establishment of a U.S. base at Planet Innovation’s Irvine facility to support commercial launch, and preparations to showcase its Guardion and LifeChain platform at a major cell and gene therapy conference, all while ending the quarter with $22.8 million in cash and term deposits and gearing up for commercial manufacturing and deployment in the second half of FY2026.

The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.

More about Vitrafy Life Sciences Ltd.

Vitrafy Life Sciences Limited is an Australian innovator in cryopreservation solutions, developing technologies for the preservation of reproductive biological material, blood products, and cell and gene therapy assets. The company targets both animal health markets, including farm animals and aquaculture, and high-value human health segments such as blood, cell and gene therapy, with a growing commercial focus in North America.

Average Trading Volume: 35,791

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$117.5M

For a thorough assessment of VFY stock, go to TipRanks’ Stock Analysis page.